The Market Herald - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • PharmAust’s phase 2 trial for treating dogs with cancer, has recruited the Animal Referral Hospital in Homebush, Sydney
  • It will join PharmAust’s current partner, the U-Vet Werribee Animal Hospital for the pivotal trial
  • This trial aims to validate previous results that showed a liquid form of MPL halted the progression of lymphoma in dogs, as well as to compare it to a new tablet formula
  • The company will continue to try and recruit further sites which will help provide clearer, more meaningful trial data
  • PharmAust is up 11.1 per cent, with shares trading at 11 cents each

PharmAust has announced recruitment guidance for its anti-cancer trial in dogs with treatment naïve B cell lymphoma.

Previously, the company’s trial showed six or seven dogs didn’t experience a progression in their cancer, with reductions in tumour size following 14 days of gelatin encapsulated liquid monepantel treatment.

PharmAust is repeating this study with a new developed GMP-grade monepantel formulation.

The animals will be assessed at 14 and 28 days of treatment to compare the performance of tablets with the capsules. Patients will then continue long-term maintenance of lower dose treatment between pet owners and veterinarians.

In September, PharmAust reached an agreement with U-Vet in Werribee, through the University of Melbourne’s Department of Veterinary Clinical Sciences, to act as a trial manager.

The trial study will be completed at the university and all required inventory has arrived on site.

U-Vet acts in a hub-and-spoke system with surrounding vet clinics in the Melbourne area to recruit eligible dogs for recruitment and treatment.

The University and PharmAust have reached a similar agreement with the Animal Referral Hospital in Homebush, Sydney.

The Homebush-based hospital conducted the previous trial using the gelatin capsules and the company is pleased it has chosen to participate again.

Additionally, PharmAust plans to work with other centres that can establish their hub-and-spoke systems with local veterinarians to facilities recruitment of dogs with cancer.

A release of trial data will occur when a clear trend becomes apparent. This will become easier the more participating sites and dogs there are involved in the trial.

“PharmAust is pleased to announce its preliminary guidance for trial recruitment and data release. PharmAust is looking forward to sharing the outcomes with shareholders as they become available,” Chief Scientific Officer Dr Richard Mollard said.

The company expects to update the market next month.

PharmAust is up 11.1 per cent, with shares trading at 11 cents each at market close.

PAA by the numbers
More From The Market Herald

Cynata Therapeutics receives approval to launch phase two trial of CYP-001 in Turkey

Cell therapy company, Cynata Therapeutics (ASX:CYP) has received regulatory and ethics approval to commence a phase…

Little Green Pharma positions itself for growth in France’s emerging medicinal cannabis market

Little Green Pharma (ASX:LGP) is primed for substantial growth after a major amendment to the French…

PolyNovo posts $8m sales month and $9m revenue month for November

Disruptive medical device company PolyNovo (ASX:PNV) has announced record monthly sales of $8.8 million for November…
Imugene (ASX:IMU) - Managing Director & CEO, Leslie Chong

Imugene set to secure European patent for cancer vaccine; announces new phase II CRC cancer trial in 2024

Imugene (ASX:IMU) is on the verge of securing approval from the European Patent Office (EPO) for…